Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


20.11.2017

1 AJR Am J Roentgenol
1 Am J Clin Pathol
2 Am J Pathol
1 Ann Oncol
4 Ann Surg Oncol
5 BMC Cancer
2 BMJ
1 Br J Cancer
2 Breast Cancer
3 Breast Cancer Res
9 Breast Cancer Res Treat
2 Breast J
1 Cancer
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Res
2 Clin Breast Cancer
1 Clin Cancer Res
1 Gene
2 Int J Cancer
1 J Clin Invest
1 J Clin Oncol
1 J Natl Cancer Inst
1 J Nucl Med
1 J Surg Oncol
2 Lancet Oncol
1 NPJ Breast Cancer
2 Oncol Rep
2 Oncology
1 PLoS Comput Biol
3 PLoS One
2 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. AGASTHYA GA, D'Orsi E, Kim YJ, Handa P, et al
    Can Breast Compression Be Reduced in Digital Mammography and Breast Tomosynthesis?
    AJR Am J Roentgenol. 2017 Sep 20:W1-W11. doi: 10.2214/AJR.16.17615.
    PubMed     Text format     Abstract available


    Am J Clin Pathol

  2. SHIN ET, Joehlin-Price AS, Agnese DM, Zynger DL, et al
    Minimal Clinical Impact of Intraoperative Examination of Sentinel Lymph Nodes in Patients With Ductal Carcinoma In Situ: An Opportunity for Improved Resource Utilization.
    Am J Clin Pathol. 2017;148:374-379.
    PubMed     Text format     Abstract available


    Am J Pathol

  3. JIAGGE E, Chitale D, Newman LA
    Triple-Negative Breast Cancer, Stem Cells, and African Ancestry.
    Am J Pathol. 2017 Nov 11. pii: S0002-9440(17)30389.
    PubMed     Text format     Abstract available

  4. DIETZE EC, Chavez TA, Seewaldt VL
    Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology.
    Am J Pathol. 2017 Nov 8. pii: S0002-9440(17)30396.
    PubMed     Text format     Abstract available


    Ann Oncol

  5. BUISSERET L, Pommey S, Allard B, Garaud S, et al
    Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  6. KANTOR O, Ajmani G, Wang CH, Datta A, et al
    The Shifting Paradigm for Breast Cancer Surgery in Patients Undergoing Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2017 Nov 10. doi: 10.1245/s10434-017-6217.
    PubMed     Text format     Abstract available

  7. KIM WH, Kim HJ, Jung JH, Park HY, et al
    Ultrasound-Guided Restaging and Localization of Axillary Lymph Nodes After Neoadjuvant Chemotherapy for Guidance of Axillary Surgery in Breast Cancer Patients: Experience with Activated Charcoal.
    Ann Surg Oncol. 2017 Nov 13. doi: 10.1245/s10434-017-6250.
    PubMed     Text format     Abstract available

  8. MCINERNEY NM, O'Neill AC, Zhong T, Hofer SOP, et al
    Response to "Complications in DIEP Flap Breast Reconstruction after Mastectomy for Breast Cancer: A Prospective Cohort Study Comparing Unilateral and Bilateral Reconstructions".
    Ann Surg Oncol. 2017 Nov 16. doi: 10.1245/s10434-017-6172.
    PubMed     Text format    

  9. LANG JE, Tereffe W, Babiera G
    Primary Locoregional Treatment in Metastatic Breast Cancer: A Reply.
    Ann Surg Oncol. 2017 Nov 16. doi: 10.1245/s10434-017-6185.
    PubMed     Text format    


    BMC Cancer

  10. KHAN UT, Walker AJ, Baig S, Card TR, et al
    Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis.
    BMC Cancer. 2017;17:747.
    PubMed     Text format     Abstract available

  11. LI J, Lai Y, Ma J, Liu Y, et al
    miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    BMC Cancer. 2017;17:745.
    PubMed     Text format     Abstract available

  12. SHIROIWA T, Fukuda T, Shimozuma K, Mouri M, et al
    Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
    BMC Cancer. 2017;17:773.
    PubMed     Text format     Abstract available

  13. ISAKOVA J, Talaibekova E, Aldasheva N, Vinnikov D, et al
    The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
    BMC Cancer. 2017;17:758.
    PubMed     Text format     Abstract available

  14. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Van de Vijver MJ, et al
    Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.
    BMC Cancer. 2017;17:755.
    PubMed     Text format     Abstract available


    BMJ

  15. IACOBUCCI G
    NICE recommends routine NHS funding for new breast cancer drugs.
    BMJ. 2017;359:j5309.
    PubMed     Text format    

  16. DYER C
    Woman who rejected breast cancer diagnosis may undergo surgery without her consent.
    BMJ. 2017;359:j5358.
    PubMed     Text format    


    Br J Cancer

  17. DANIELS B, Kiely BE, Houssami N, Lord SJ, et al
    Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Breast Cancer

  18. KASSEM L, Shohdy KS, Lasheen S, Abdel-Rahman O, et al
    Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
    Breast Cancer. 2017 Nov 16. doi: 10.1007/s12282-017-0818.
    PubMed     Text format     Abstract available

  19. WANG R, Li J, Zhao Y, Li Y, et al
    Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis.
    Breast Cancer. 2017 Nov 14. doi: 10.1007/s12282-017-0816.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  20. HROMAS R, Kim HS, Sidhu G, Williamson E, et al
    The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
    Breast Cancer Res. 2017;19:122.
    PubMed     Text format     Abstract available

  21. AMANATULLAH DF, Tamaresis JS, Chu P, Bachmann MH, et al
    Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells.
    Breast Cancer Res. 2017;19:121.
    PubMed     Text format     Abstract available

  22. OHNSTAD HO, Borgen E, Falk RS, Lien TG, et al
    Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Breast Cancer Res. 2017;19:120.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  23. CHOI BH, Choi N, Kim MY, Yang JH, et al
    Correction to: Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat. 2017 Nov 14. doi: 10.1007/s10549-017-4568.
    PubMed     Text format     Abstract available

  24. BOSTNER J, Alayev A, Berman AY, Fornander T, et al
    Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4508.
    PubMed     Text format     Abstract available

  25. ABDEL-RAHMAN O
    Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.
    Breast Cancer Res Treat. 2017 Nov 15. doi: 10.1007/s10549-017-4577.
    PubMed     Text format     Abstract available

  26. RIER HN, Jager A, Sleijfer S, van Rosmalen J, et al
    Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 17. doi: 10.1007/s10549-017-4574.
    PubMed     Text format     Abstract available

  27. GILLMAN AS, Gardiner CK, Koljack CE, Bryan AD, et al
    Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.
    Breast Cancer Res Treat. 2017 Nov 10. doi: 10.1007/s10549-017-4573.
    PubMed     Text format     Abstract available

  28. HAYES SC, Steele ML, Spence RR, Gordon L, et al
    Correction to: Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat. 2017 Nov 10. doi: 10.1007/s10549-017-4569.
    PubMed     Text format     Abstract available

  29. MIJWEL S, Backman M, Bolam KA, Jervaeus A, et al
    Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial.
    Breast Cancer Res Treat. 2017 Nov 14. doi: 10.1007/s10549-017-4571.
    PubMed     Text format     Abstract available

  30. MENESES K, Benz R, Bail JR, Vo JB, et al
    Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4564.
    PubMed     Text format     Abstract available

  31. DODSON A, Okonji D, Assersohn L, Rigg A, et al
    Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4514.
    PubMed     Text format     Abstract available


    Breast J

  32. WEINBERG MS, Shachar SS, Muss HB, Deal AM, et al
    Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population.
    Breast J. 2017 Nov 15. doi: 10.1111/tbj.12952.
    PubMed     Text format     Abstract available

  33. PASSHAK M, Shachar SS, Bar-Sela G, Fried G, et al
    Breast cancer in young women aged 35 and under: Patterns of care and outcome.
    Breast J. 2017 Nov 15. doi: 10.1111/tbj.12966.
    PubMed     Text format    


    Cancer

  34. PRINTZ C
    Physicians discuss ramifications of studies pointing to breast cancer overdiagnosis: New research under way attempts to better define who should be screened and treated.
    Cancer. 2017;123:4525-4527.
    PubMed     Text format    


    Cancer Epidemiol Biomarkers Prev

  35. WINTERS-STONE K, Wood LJ, Stoyles S, Dieckmann N, et al
    The Effects of Resistance Exercise on Biomarkers of Breast Cancer Prognosis: A Pooled Analysis of Three Randomized Trials.
    Cancer Epidemiol Biomarkers Prev. 2017 Nov 15. pii: cebp.0766.2017.
    PubMed     Text format     Abstract available


    Cancer Res

  36. TURCOTTE M, Allard D, Mittal D, Bareche Y, et al
    CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
    Cancer Res. 2017;77:5652-5663.
    PubMed     Text format     Abstract available

  37. PALMER JR, Castro-Webb N, Bertrand K, Bethea TN, et al
    Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women.
    Cancer Res. 2017;77:6462-6469.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  38. GRANDI G, Toss A, Cagnacci A, Marcheselli L, et al
    Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History.
    Clin Breast Cancer. 2017 Nov 14. pii: S1526-8209(17)30488.
    PubMed     Text format     Abstract available

  39. HAYASHI N, Takahashi Y, Matsuda N, Tsunoda H, et al
    The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Clin Breast Cancer. 2017 Oct 3. pii: S1526-8209(17)30319.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  40. AUSHEV VN, Lee E, Zhu J, Gopalakrishnan K, et al
    Novel predictors of breast cancer survival derived from miRNA activity analysis.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0996.2017.
    PubMed     Text format     Abstract available


    Gene

  41. PENG R, Luo C, Guo Q, Cao J, et al
    Association analyses of genetic variants in long non-coding RNA MALAT1 with breast cancer susceptibility and mRNA expression of MALAT1 in Chinese Han population.
    Gene. 2017 Nov 13. pii: S0378-1119(17)30956-3. doi: 10.1016/j.gene.2017.
    PubMed     Text format     Abstract available


    Int J Cancer

  42. BRANDT J, Borgquist S, Almgren P, Forsti A, et al
    Thyroid associated genetic polymorphisms in relation to breast cancer risk in the Malmo Diet and Cancer Study.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31156.
    PubMed     Text format     Abstract available

  43. SCHAIRER C, Pfeiffer RM, Gadalla SM
    Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.
    Int J Cancer. 2017 Nov 16. doi: 10.1002/ijc.31148.
    PubMed     Text format     Abstract available


    J Clin Invest

  44. WANG S, Liang K, Hu Q, Li P, et al
    JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.
    J Clin Invest. 2017 Nov 13. pii: 91553. doi: 10.1172/JCI91553.
    PubMed     Text format     Abstract available


    J Clin Oncol

  45. HENRY NL, Unger JM, Schott AF, Fehrenbacher L, et al
    Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
    J Clin Oncol. 2017 Nov 14:JCO2017746651. doi: 10.1200/JCO.2017.74.6651.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  46. SCHWARZ LJ, Hutchinson KE, Rexer BN, Estrada MV, et al
    An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    J Nucl Med

  47. ULANER GA, Lyashchenko SK, Riedl C, Ruan S, et al
    First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer.
    J Nucl Med. 2017 Nov 16. pii: jnumed.117.202010. doi: 10.2967/jnumed.117.202010.
    PubMed     Text format     Abstract available


    J Surg Oncol

  48. ONEGA T, Weiss JE, Goodrich ME, Zhu W, et al
    Relationship between preoperative breast MRI and surgical treatment of non-metastatic breast cancer.
    J Surg Oncol. 2017 Nov 11. doi: 10.1002/jso.24796.
    PubMed     Text format     Abstract available


    Lancet Oncol

  49. MARTIN M, Holmes FA, Ejlertsen B, Delaloge S, et al
    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30717.
    PubMed     Text format     Abstract available

  50. CHAVEZ-MACGREGOR M, Mittendorf EA
    Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions.
    Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30844.
    PubMed     Text format    


    NPJ Breast Cancer

  51. SPARANO JA, Gray R, Oktay MH, Entenberg D, et al
    A metastasis biomarker (MetaSite Breast Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer.
    NPJ Breast Cancer. 2017;3:42.
    PubMed     Text format     Abstract available


    Oncol Rep

  52. ZHANG W, Pan Y, Gou P, Zhou C, et al
    Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6094.
    PubMed     Text format     Abstract available

  53. AOTO K, Mimura K, Okayama H, Saito M, et al
    Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma.
    Oncol Rep. 2017 Nov 14. doi: 10.3892/or.2017.6097.
    PubMed     Text format     Abstract available


    Oncology

  54. KAWAHARA T, Shimozuma K, Shiroiwa T, Hagiwara Y, et al
    Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer.
    Oncology. 2017 Nov 17. doi: 10.1159/000484142.
    PubMed     Text format     Abstract available

  55. HOKIMOTO N, Sugimoto T, Namikawa T, Funakoshi T, et al
    A Novel Color Fluorescence Navigation System for Intraoperative Transcutaneous Lymphatic Mapping and Resection of Sentinel Lymph Nodes in Breast Cancer: Comparison with the Combination of Gamma Probe Scanning and Visible Dye Methods.
    Oncology. 2017 Nov 10. doi: 10.1159/000484050.
    PubMed     Text format     Abstract available


    PLoS Comput Biol

  56. ROMAN T, Xie L, Schwartz R
    Automated deconvolution of structured mixtures from heterogeneous tumor genomic data.
    PLoS Comput Biol. 2017;13:e1005815.
    PubMed     Text format     Abstract available


    PLoS One

  57. HIRONAKA-MITSUHASHI A, Matsuzaki J, Takahashi RU, Yoshida M, et al
    A tissue microRNA signature that predicts the prognosis of breast cancer in young women.
    PLoS One. 2017;12:e0187638.
    PubMed     Text format     Abstract available

  58. SYED S, Schober J, Blanco A, Zustiak SP, et al
    Morphological adaptations in breast cancer cells as a function of prolonged passaging on compliant substrates.
    PLoS One. 2017;12:e0187853.
    PubMed     Text format     Abstract available

  59. CARLSEN JF, Ewertsen C, Sletting S, Talman ML, et al
    Strain histograms are equal to strain ratios in predicting malignancy in breast tumours.
    PLoS One. 2017;12:e0186230.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  60. BEAUSANG JF, Wheeler AJ, Chan NH, Hanft VR, et al
    T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire.
    Proc Natl Acad Sci U S A. 2017 Nov 14. pii: 201713863.
    PubMed     Text format     Abstract available


  61. Correction for Sansone et al., Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer.
    Proc Natl Acad Sci U S A. 2017 Nov 13. pii: 201718630.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: